COVID-19 in Parkinson’s Disease Patients Living in Lombardy, Italy
Fasano et al.
, COVID-19 in Parkinson’s Disease Patients Living in Lombardy, Italy
, Movement Disorders, doi:10.1002/mds.28176
Retrospective phone survey of 1,486 Parkinson's disease patients in Italy, showing lower risk of COVID-19 cases with vitamin D supplementation. This paper also presents a case control study of PD patients and family member control patients.
risk of case, 42.0% lower, RR 0.58, p = 0.048, treatment 13 of 329 (4.0%), control 92 of 1,157 (8.0%), NNT 25, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Fasano et al., 2 Jun 2021, retrospective, Italy, peer-reviewed, 7 authors, dosage not specified.
Abstract: BRIEF REPORT
COVID-19 in Parkinson’s Disease
Patients Living in Lombardy, Italy
Alfonso Fasano, MD PhD,1,2
Emanuele Cereda, MD PhD,3* Michela Barichella, MD,4,5
Erica Cassani, MD,5,6 Valentina Ferri, MD,5,6
Anna Lena Zecchinelli, MD,6 and Gianni Pezzoli, MD5,6
Edmond J. Safra Program in Parkinson’s Disease and the Morton
and Gloria Shulman Movement Disorders Centre, Toronto Western
Hospital, UHN, Division of Neurology, University of Toronto,
Toronto, Ontario, Canada 2Krembil Brain Institute, Toronto, Ontario,
Canada 3Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
UOS Clinical Nutrition, Pini-CTO, Milan, Italy 5Fondazione Grigioni
per il Morbo di Parkinson, Italy 6Parkinson Institute, Pini-CTO,
A B S T R A C T : Background: It is unknown whether
patients with PD are at greater risk of COVID-19, what
their risk factors are, and whether their clinical manifestations differ from the general population.
Objectives: The study aimed to address all these issues.
Methods: In a case-controlled survey, we interviewed
1,486 PD patients attending a single tertiary center in
Lombardy, Italy and 1,207 family members (controls).
Results: One hundred ﬁve (7.1%) and 92 controls
(7.6%) were identiﬁed as COVID-19 cases. COVID-19
patients were younger, more likely to suffer from chronic
obstructive pulmonary disease, to be obese, and vitamin
D nonsupplemented than unaffected patients. Six
patients (5.7%) and 7 family members (7.6%) died from
COVID-19. Patients were less likely to report shortness
of breath and require hospitalization.
Conclusions: In an unselected large cohort of nonadvanced PD patients, COVID-19 risk and mortality did
not differ from the general population, but symptoms
appeared to be milder. The possible protective role of vitamin D supplementation warrants future studies. © 2020
International Parkinson and Movement Disorder Society
- - - - - - - - - - - - - - -to:- - Dr.
- - - Emanuele
- - - - - - - - -Cereda,
- - - - - - Clinical
- - - - - - -Nutrition
- - - - - - -and
------Dietetics Unit, Fondazione IRCCS Policlinico San Matteo, Viale Golgi
19, 27100 Pavia, Italy; E-mail: firstname.lastname@example.org
Relevant conﬂicts of interest/ﬁnancial disclosures: Nothing to report.
Full ﬁnancial disclosures and author roles may be found in the online
version of this article.
Funding agencies: This work was supported by “Fondazione Grigioni
per il Morbo di Parkinson.”
Received: 12 May 2020; Revised: 25 May 2020; Accepted: 27
Published online 26 June 2020 in Wiley Online Library
(wileyonlinelibrary.com). DOI: 10.1002/mds.28176
Severe acute respiratory syndrome coronavirus
2 (SARS Co-V2) emerged in the region of Wuhan in
China around December last year and spread so rapidly
that the World Health Organization declared coronavirus disease 2019 (COVID-19) a pandemic on 11 March
2020.1 Speciﬁc pre-existing medical conditions and
advanced age appear to be linked to more severe manifestations of the infection,1,2 thus raising the question
of whether Parkinson’s disease (PD) poses an increased
risk of morbidity and mortality in COVID-19 patients.3
The ﬁrst reported case of COVID-19 in a 74-year-old
PD patient complicated by encephalopathy has recently
been described.4 A series of 10 PD patients collected in
Padua, Italy and London, United Kingdom reported a
high mortality rate (40%), and worsening of anxiety
and other nonmotor features,5 in keeping with a recent
survey among patients and caregivers.6 We..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.